SOURCE: SciClone Pharmaceuticals, Inc.

March 17, 2008 06:30 ET

SciClone Hosts Thymalfasin Symposium at Asian Pacific Association for the Study of the Liver

Experts Present Therapeutic Strategies for Hepatitis B & C

FOSTER CITY, CA--(Marketwire - March 17, 2008) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to host a symposium at the 18th annual meeting of the Asian Pacific Association for the Study of the Liver (APASL), in Seoul, Korea on Tuesday, March 25, 2008.

The symposium, "Therapeutic Strategies for Hepatitis B & C - Treatment Regimens Using Thymosin a-1, an Immunomodulator," will take place on March 25, 2008, from 3:00 to 4:00 p.m. local time, at the COEX Convention Center in Seoul, Korea.

Experts in the field of liver disease will discuss ZADAXIN®, generically referred to as thymalfasin or thymosin alpha 1, and its therapeutic benefits as a treatment for hepatitis B and hepatitis C.

--  Yun-Fan Liaw, M.D., Professor of Medicine in the Liver Research Unit
    at Chang Gung University and Memorial Hospital in Taipei, Taiwan, will
    discuss ZADAXIN as an immunomodulatory treatment for patients infected with
    the hepatitis B virus.
--  Mario Rizzetto, M.D., Professor of Gastroenterology at San Giovanni
    Battista Hospital of the University of Torino in Torino, Italy, and the
    Principal Investigator for a nearly completed phase 3 hepatitis C triple
    therapy trial in Europe, will follow with a presentation on the use of
    triple therapy (pegylated interferon, ribavirin and thymalfasin) in the
    treatment of hepatitis C non-responder patients.
--  Kyusung Rim, MD, the 2007 congress chairman for the Korean Association
    for the Study of the Liver will serve as the meeting chairman and

"APASL is an important forum that provides the most current, innovative and advanced therapeutic technologies to prominent physicians specializing in the treatment of liver disease in Asia," commented Hans P. Schmid, President and Managing Director of SciClone Pharmaceuticals International Limited. "We are pleased to have respected experts such as Drs. Liaw and Rizzetto present thymalfasin's efficacy and safety data in the treatment of patients infected with the hepatitis B and hepatitis C viruses."

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of hepatitis C and malignant melanoma. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in the rapidly growing Chinese pharmaceutical market by in-licensing or acquiring the marketing rights to other products, such as DC Bead™. For the U.S. market, SciClone's other clinical-stage drug development candidates are RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of hepatitis C. For more information about SciClone, visit

Contact Information

  • Corporate Contact:
    Richard Waldron
    Executive Vice President & Chief Financial Officer
    SciClone Pharmaceuticals, Inc.
    (650) 358-3437